 |
Diabetes mellitus type-2 - incidence +30% since 1990 - persons in their 30s: +70% - health care expenditure: more than cancer - preceded by insulin resistance Hypertension - often associated with diabetes - incidence approx. 25% - even if treated, yet higher mortality Associated metabolic disorders - hypertriglyceridemia - hyperuricemia - many others |
| Unfavourable lifestyle
Unhealthy diets BMI calculation BMI and BP Salt intake Alcohol Hypertension BMI and SNS Hyperkinetic HT Established HT Systolic HT Renin / Angiotensin II
Diabetes type-2
Therapy International Society for Molecular Nutrition and Therapy other sites maintained by us: www.cardiorepair.com www.carditis.com www.herzzentrum-marburg.de www.physio.carditis.de |
The
site focusses on links between lifestyle, sympathetic
overactivity and cardiovascular disease. Therapeutics are
described which counteract sympathetic overactivity by
reducing catecholamine release: the centrally acting
imidazoline I1 receptor agonist moxonidine and the
angiotensin receptor blocker (ARB) eprosartan with a high
presynaptic inhibitory action on norepinephrine release. Since eprosartan has a unique structure, i.e. the first non-tetrazol and non-biphenyl ARB, it differs from other ARBs by inhibiting more potently presynaptic norepinephrine release. Eprosartan controls high blood pressure by a "dual mechanism of action". Based on this dual mechanism of action, the "Teveten Song - The Power of Two" has been composed and presented by the singers Ogie and Janno on occasion of the Teveten Launch in Manila, May 27, 2003. An update focuses on "Addominal fat and sympathetic overactivity - from calorie intake to postmenopausal hypertension" |